Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Clin Rheumatol ; 35(3): 751-7, 2016 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-25344777

RESUMO

Information on the epidemiology of rheumatoid arthritis (RA) in Southern Europe is scarce. We estimated the age- and gender-adjusted incidence and prevalence of RA in Catalonia using routinely collected primary care records. We identified incident (2009-2012) and prevalent (on 31 December 2012) cases of RA in the SIDIAP database using ICD-10 codes. SIDIAP contains anonymized data from computerized primary care records for about five million adults (>80 % of the population). We estimated age- (5-year groups) and gender-specific, and directly standardized incidence and prevalence of RA and confidence intervals (95% CIs) assuming a Poisson distribution. A total of 20,091 prevalent (among whom 5,796 incident) cases of RA were identified among 4,796,498 study participants observed for up to 4 years. Rates of RA increased with age in both genders, peaking at the age of 65-70 years. Age- and gender-standardized incidence and prevalence rates were 0.20/1,000 person-years (95% CI 0.19-0.20) and 4.17/1,000 (4.11-4.23) respectively. Rheumatoid factor was positive (≥10 IU/mL) in 1,833 (73.9 %) of 2,482 cases tested in primary care. The incidence and prevalence of RA in Catalonia are similar to those of other Southern European regions, and lower than those of northern areas. This data will inform health care planning and resource allocation.


Assuntos
Artrite Reumatoide/epidemiologia , Adolescente , Adulto , Distribuição por Idade , Idoso , Idoso de 80 Anos ou mais , Bases de Dados Factuais , Registros Eletrônicos de Saúde , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Espanha/epidemiologia , Adulto Jovem
2.
An Pediatr (Barc) ; 67(4): 362-7, 2007 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-17949646

RESUMO

INTRODUCTION: We review the scientific evidence on the safety of the measles, mumps, and rubella (MMR) vaccine (produced in chicken embryo cell culture) in children with egg allergy. Data on the reactogenicity observed with this vaccine in a large series of children with this type of allergy immunized in an hospital immunization unit are presented. MATERIAL AND METHODS: An observational prospective study was performed in the International Immunization Unit of the Epidemiology and Preventive Medicine Service of the Vall d'Hebron University Hospital from March 2004 to December 2005. Demographic variables, clinical history of allergy, and the adverse reactions observed 30 minutes after vaccine administration were analyzed. RESULT: A total of 140 patients (106 referred for the first MMR vaccine dose, and 34 for the second) were evaluated. Of these, 75.7 % showed clinical signs after egg ingestion (severe reactions were described in only seven patients: respiratory distress in six and systemic anaphylaxis in one). The MMR vaccine was administered to 121 children. No significant adverse reactions were observed (17.8 % of the vaccinated children developed mild local symptoms). CONCLUSIONS: According to current scientific evidence and the data obtained in this study, the MMR vaccine is safe in patients with egg allergy.


Assuntos
Serviços de Saúde da Criança , Hipersensibilidade a Ovo/imunologia , Departamentos Hospitalares/estatística & dados numéricos , Programas de Imunização/estatística & dados numéricos , Imunização , Vacina contra Sarampo-Caxumba-Rubéola/imunologia , Criança , Feminino , Humanos , Masculino , Estudos Prospectivos , Espanha/epidemiologia
3.
An. pediatr. (2003, Ed. impr.) ; 67(4): 362-367, oct. 2007. tab
Artigo em Es | IBECS | ID: ibc-056412

RESUMO

Introducción En este estudio se revisan las evidencias científicas disponibles sobre la seguridad de la vacuna triple vírica convencional (cultivada en fibroblastos de embriones de pollo) en niños con alergia al huevo, y se evalúa la reactogenicidad vacunal en una serie amplia de niños con este tipo de alergia inmunizados con triple vírica en una unidad de vacunación hospitalaria. Material y métodos Estudio observacional prospectivo, realizado en la Unidad de Vacunación Internacional del Servicio de Medicina Preventiva y Epidemiología del Hospital Universitario Vall d'Hebron, entre marzo de 2004 y diciembre de 2005. Se analizan variables demográficas, las relativas a los antecedentes de alergia y la reactogenicidad apreciada tras la observación directa del niño durante los 30 min posteriores a la vacunación. Resultados Se han incluido en el estudio 140 pacientes (106 en primera dosis de vacuna triple vírica y 34 en segunda). El 75,7 % había presentado manifestaciones clínicas tras la ingesta de huevo o de alimentos que lo contenían (sólo siete niños habían presentado manifestaciones graves, en forma de dificultad respiratoria en 6 casos y de anafilaxia en uno). Se administró la vacuna convencional a 121 niños, y no se observó ninguna reacción adversa importante (el 17,8 % de ellos presentó reacción local leve en el punto de inyección). Conclusiones Las evidencias científicas actuales, así como los datos del presente estudio, sustentan la seguridad de la vacuna triple vírica en personas con hipersensibilidad al huevo


Introduction We review the scientific evidence on the safety of the measles, mumps, and rubella (MMR) vaccine (produced in chicken embryo cell culture) in children with egg allergy. Data on the reactogenicity observed with this vaccine in a large series of children with this type of allergy immunized in an hospital immunization unit are presented. Material and methods An observational prospective study was performed in the International Immunization Unit of the Epidemiology and Preventive Medicine Service of the Vall d'Hebron University Hospital from March 2004 to December 2005. Demographic variables, clinical history of allergy, and the adverse reactions observed 30 minutes after vaccine administration were analyzed. Result A total of 140 patients (106 referred for the first MMR vaccine dose, and 34 for the second) were evaluated. Of these, 75.7 % showed clinical signs after egg ingestion (severe reactions were described in only seven patients: respiratory distress in six and systemic anaphylaxis in one). The MMR vaccine was administered to 121 children. No significant adverse reactions were observed (17.8 % of the vaccinated children developed mild local symptoms). Conclusions According to current scientific evidence and the data obtained in this study, the MMR vaccine is safe in patients with egg allergy


Assuntos
Masculino , Feminino , Criança , Humanos , Vacina contra Sarampo-Caxumba-Rubéola/imunologia , Vacinação/efeitos adversos , Proteínas Dietéticas do Ovo/imunologia , Medicina Baseada em Evidências , Esquemas de Imunização , Vacinas Combinadas/administração & dosagem , Estudos Prospectivos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...